Background-The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that bivalirudin monotherapy significantly reduces major bleeding compared with heparin (unfractionated or enoxaparin) or bivalirudin plus a glycoprotein IIb/IIIa inhibitor in acute coronary syndromes. Whether vascular closure devices (VCD) impact these results is unknown. Therefore, this study sought to determine whether VCD impact major access site bleeding (ASB) in patients with acute coronary syndromes undergoing early invasive management by the femoral approach. Methods and Results-Major ASB in ACUITY was defined as ASB requiring interventional or surgical correction, hematoma Ն5 cm at the access site, retroperitoneal bleeding, or hemoglobin drop Ն3 g/dL with ecchymosis or hematoma Ͻ5 cm, oozing blood, or prolonged bleeding (Ͼ30 minutes) at the access site. Stepwise logistical regression was performed to identify the independent determinants of ASB. Of 11 621 patients undergoing angiography with or without percutaneous coronary intervention by the femoral approach, 4307 (37.1%) received a VCD and 7314 (62.9%) did not. Rates of major ASB were lower with VCD compared with no VCD (2.5% versus 3.3%, relative risk, 0.76; 95% CI, 0.61 to 0.94; Pϭ0.01) and were lowest in patients treated with bivalirudin monotherapy and a VCD (0.7%). Stepwise logistic regression revealed that a VCD (odds ratio, 0.78; 95% CI, 0.61 to 0.99; Pϭ0.04) and bivalirudin monotherapy (odds ratio, 0.35; 95% CI, 0.25 to 0.49; PϽ0.0001) were both independent determinates of freedom from major ASB. Conclusion-In patients with acute coronary syndromes undergoing an early invasive management strategy by the femoral approach, the use of a VCD, bivalirudin monotherapy, or both minimizes rates of major ASB. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00093158.
V ascular closure devices (VCD) have been shown to significantly reduce hemostasis and ambulation times after diagnostic coronary angiography and percutaneous coronary intervention (PCI); however, several meta-analyses and a large registry from the American College of Cardiology-National Cardiovascular Data Registry have reported conflicting data on whether VCD increase, decrease, or do not alter the risk of access site bleeding (ASB). [1] [2] [3] [4] [5] [6] [7] The prospective, multicenter, randomized Acute Catheterization
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and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that moderate and high-risk patients with acute coronary syndromes (ACS) undergoing an early invasive strategy had significantly reduced rates of major bleeding with bivalirudin monotherapy compared with heparin (unfractionated or enoxaparin) or bivalirudin plus a glycoprotein IIb/IIIa inhibitor (GPI). 8 To assess the impact of VCD and the antithrombotic regimen on rates of ASB, we analyzed patients with ACS managed invasively by the femoral access site from the large-scale contemporary ACUITY trial.
Methods

Study Design
The ACUITY trial study design has been previously described in detail. 9 Briefly, patients older than 18 years with symptoms of unstable angina lasting for at least 10 minutes within the preceding 24 hours were eligible for enrollment if 1 or more of the following criteria were met: (1) new ST-segment depression or transient elevation of at least 1 mm; (2) elevated troponin I, troponin T, or creatine kinase-MB (CKMB) levels; (3) known coronary artery disease; or (4) all 4 other thrombolysis in myocardial infarction risk criteria. 10 Exclusion criteria included acute ST-segment-elevation myocardial infarction or shock; bleeding diathesis or major bleeding within 2 weeks; thrombocytopenia; creatinine clearance Ͻ30 mL/ min; and recent administration of abciximab, bivalirudin, or Ͼ1 dose of low-molecular-weight heparin. The study was approved by institutional review boards or ethics committees at each center, and all patients gave informed written consent.
Randomization and Study Procedures
The ACUITY trial randomized 13 819 patients to receive heparin (unfractionated or enoxaparin) plus GPI, bivalirudin plus GPI, or bivalirudin monotherapy in an open-label fashion. Unfractionated heparin was administrated intravenously (IV) as a 60 IU/kg bolus plus 12 IU kg/h infusion to achieve an activated partial thromboplastin time of 50 to 75 seconds before angiography and an activated clotting time of 200 to 250 seconds during PCI. Enoxaparin was administered 1 mg/kg subcutaneously twice daily before angiography with a 0.3-mg/kg IV bolus immediately before PCI if the last subcutaneous dose was Ͼ8 hours earlier or 0.75 mg/kg if Ͼ16 hours earlier. Bivalirudin was administered IV as a 0.1 mg/kg bolus plus 0.25 mg/kg/h infusion, with a bolus of 0.5 mg/kg and an increase in the infusion to 1.75 mg/kg/h before PCI. Patients assigned to 1 of the GPI arms were further randomized in a 2ϫ2 factorial design to either upstream GPI immediately after randomization or deferred (before PCI). Provisional GPI was permitted in deferred GPI or bivalirudin monotherapy patients for severe breakthrough ischemia and during PCI in bivalirudin monotherapy patients for prespecified criteria. The GPI was administered per labeling and continued 12 to 18 hours after PCI. Per protocol, angiography was intended in all patients within 72 hours of randomization with subsequent triage to PCI, coronary artery bypass graft surgery (CABG), or medical management. Aspirin was administered daily during hospitalization (300 to 325 mg PO or 250 to 500 mg IV). Thienopyridine dosing and timing were left to investigator discretion; however, the protocol required a clopidogrel loading dose of 300 mg or more within 2 hours after PCI in all cases. Clopidogrel (75 mg daily) was recommended for 1 year in all patients undergoing PCI, and aspirin (75 to 325 mg daily) was indefinitely recommended. The choice of the arterial access site, the decision whether to use a vascular closure device, and which device to use were left to the discretion of the physician investigator. Although the performance of femoral angiography is recommended before the use of a VCD, this information was not collected in this analysis. Sheath removal, manual compression, and ambulation protocols were determined by the individual institutions.
End Points and Statistical Analyses
End points were assessed at 30 days. For the purpose of the present analysis, major ASB (not related to CABG) was defined as ASB requiring interventional or surgical correction, hematoma Ն5 cm at the access site, retroperitoneal bleeding, or hemoglobin drop Ն3 g/dL with ecchymosis or hematoma Ͻ5 cm, oozing blood or prolonged bleeding (Ͼ30 minutes) at the access site. All analyses are by intention to treat. Stepwise logistical regression was performed to identify the independent determinants of ASB. The variables used in the regression model were age Ն75 years, anemia, baseline elevation CKMB/troponin, creatinine clearance Ͻ60 mL/min, closure device use, diabetes, baseline ST-segment deviation, gender, hyperlipidemia, hypertension, prior myocardial infarction, prior PCI, prior CABG, randomization to bivalirudin versus heparin plus GPI, randomization to bivalirudin plus GPI versus heparin plus GPI, and thienopyridine use before angiography/PCI. A P value of Ͻ0.05 was required for statistical significance. Statistical analyses were performed by SAS version 8.2 (SAS Institute Inc, Cary, NC).
Results
Patient Population
Between August 23, 2003, and December 5, 2005, 13 819 patients with ACS were enrolled at 450 academic and community-based centers in 17 countries and randomized to heparin (unfractionated or enoxaparin) plus GPI, bivalirudin plus GPI, or bivalirudin monotherapy. Access site information was only collected for the first coronary angiography procedure. Patients undergoing deferred PCI, in whom a different access site was potentially used, were therefore excluded from the present analysis (nϭ28), as were patients with brachial access (nϭ90), radial access (nϭ798) or those whose records lacked access site (nϭ914) or VCD use (nϭ368) information. After excluding these patients, the study population consisted of 11 621 patients who underwent coronary angiography with or without PCI by the femoral approach.
Of the 11 621 patients in the study population, 4307 (37.1%) received a VCD (2971 AngioSeal, 1113 Perclose, 109 VasoSeal, 33 Duett, and 81 other or unknown) and 7314 (62.9%) did not. Baseline characteristics and demographics are presented in Table 1 . Patients who received a VCD were generally a lower risk population compared with those who did not; they were younger in age and had lower rates of diabetes, hypertension, anemia, baseline renal insufficiency, prior myocardial infarction, and prior CABG. Furthermore, patients who received a VCD were less likely to have elevated biomarkers at baseline.
VCD and Major ASB
The rates of major ASB were significantly lower in patients who received a VCD compared with those who did not (2.5% versus 3.3%; relative risk, 0.75; 95% CI, 0.61 to 0.94; Pϭ0.01). Furthermore, because major ASB represented Ͼ60% of ACUITY non-CABG major bleeding, 8 ACUITY non-CABG major bleeding was also lower in those patients who received a VCD compared with those who did not (3.9% versus 5.3%; relative risk, 0.72; 95% CI, 0.61 to 0.86; Pϭ0.0003). The individual components of major ASB occurred with similar frequency in patients with and without a VCD, except for ASB requiring interventional or surgical correction and hematoma Ն5 cm at the puncture site, which occurred significantly less often in those patients with a VCD ( Table 2 ). Unadjusted rates of major ASB were 3.0% for AngioSeal, 1.4% for Perclose, and 1.3% for VasoSeal, Duett, and other or unknown VCD (Pϭ0.006 for the comparison of AngioSeal with Perclose). In terms of the individual components of major ASB, there was an unadjusted trend toward more hematoma Ն5 cm at the puncture site with AngioSeal compared with Perclose (1.6% versus 0.8%, Pϭ0.064). All other components of major ASB were similar. No significant differences were observed in the baseline characteristics of patients in the 3 randomized antithrombin groups with or without VCD usage (data not shown). The rates of major ASB were significantly lower in patients treated with bivalirudin monotherapy compared with heparin plus GPI, regardless of whether a VCD was used (0.7% versus 3.3%, respectively, PϽ0.001) or was not used (1.9% versus 4.2%, respectively, PϽ0.0001; Figure 1 ).
The impact of VCD on major ASB overall and among the 3 randomized treatment arms was also evaluated in the subset of patients in whom PCI was immediately performed after diagnostic angiography (nϭ6606, VCD used in 2451 [37.1%] patients and not used in 4155 [62.9%] patients). Among patients undergoing PCI, a trend was present toward reduced rates of major ASB among patients who received a VCD versus those who did not (3.6% versus 4.5%, Pϭ0.08; Figure  2 ). As observed in the overall population, ASB requiring interventional or surgical correction and hematoma Ն5 cm occurred significantly less often in patients undergoing PCI when a VCD was used (0.4% versus 0.8%, Pϭ0.05 and 1.9% versus 2.7%, Pϭ0.03, respectively). Also consistent with the overall population, in patients undergoing PCI who received a VCD, major ASB was more frequent with AngioSeal compared with Perclose (4.3% versus 2.1%, Pϭ0.01). ASB was lowest in patients who received bivalirudin monotherapy compared with heparin plus GPI regardless of whether a VCD was used (0.8% versus 4.7%, PϽ0.0001) or was not used (2.4% versus 5.7%, PϽ0.0001). As shown in Table 3 , a stepwise logistic regression revealed that treatment with bivalirudin monotherapy rather than heparin plus a GPI was the strongest predictor of freedom from major ASB (odds ratio, 0.35; 95% CI, 0.25 to 0.49; PϽ0.0001). The use of a VCD was also independently associated with freedom from major ASB (odds ratio, 0.78, 95% CI, 0.61 to 0.99; Pϭ0.04). When age was inserted into the multivariate model as a continuous rather than a discrete variable, VCD use was borderline significant (odds ratio, 0.80; 95% CI, 0.62 to 1.02; Pϭ0.066). In addition, female sex, age Ն75 years, elevated baseline cardiac biomarkers, thienopyridine use before angiography or PCI, and no prior PCI were independently associated with major ASB. Other variables in this model that were not independently associated with major ASB included anemia, baseline renal insufficiency (creatinine clearance Ͻ60 mL/min), diabetes mellitus, ST-segment deviation at baseline, hyperlipidemia, prior myocardial infarction, and prior CABG.
Discussion
The ACUITY trial demonstrated that compared with antithrombin regimens containing a GPI, bivalirudin monotherapy significantly reduces major and minor bleeding complications, including ASB, without increasing ischemic complications in patients with moderate and high-risk ACS managed with an early invasive strategy. Although femoral VCD were initially demonstrated to reduce time to hemostasis and ambulation, 2-4 data regarding their impact on bleeding from the access site has been at variance. [5] [6] [7] [8] Several of the early meta-analyses examining the rate of vascular complications with VCD 5-7 were based on early reports of firstgeneration devices with many of the operators still in the "learning curve" phase. Closure devices have considerably improved in terms of their size and ease of use since these early reports, as have operator experience and technique with VCD. Antiplatelet and anticoagulant regimens during angiography and PCI have also evolved since these early reports. The present analysis was therefore performed to evaluate the impact of femoral VCD on major ASB in a contemporary clinical trial of moderate and high-risk patients with ACS undergoing an early invasive management strategy.
In this analysis of patients undergoing angiography with or without PCI from the femoral approach, there was a significant reduction in the incidence of major ASB and ACUITY non-CABG major bleeding when a VCD was used. In terms of the individual components of major ASB, both ASB requiring interventional or surgical correction and hematoma Ն5 cm at the puncture site occurred significantly less often in those patients with a VCD. Furthermore, the lowest rate of ASB (Ͻ1%) was observed when patients were treated with bivalirudin monotherapy and a VCD. Stepwise logistic regression revealed significantly reduced risks in the odds of major ASB with bivalirudin monotherapy or VCD usage (65% and 22%, respectively). The magnitudes of these results in the setting of a clinical trial are very similar and concordant to those recently reported from the large Northern New England PCI Registry in which the relative risk reduction in bleeding and vascular complications with bivalirudin and VCD use during PCI was 52% and 25%, respectively. 11 Because bleeding has been found to be a powerful independent predictor of 30-day mortality in patients with ACS managed invasively in the ACUITY, the Organization to Assess Ischemic Syndromes Registry, and the Clopidogrel in Unstable Angina to Prevent Recurrent Events randomized trials, the present findings of reduced major ASB and ACUITY non-CABG major bleeding using femoral VCD in concert with bivalirudin may have significant clinical implications for future improvements. 12, 13 We have also reported that the use of the radial artery access site is associated with a significantly lower rate of major bleeding complications in comparison with the more conventional femoral artery access route, and that bivalirudin monotherapy compared with heparin plus GPI significantly reduced access site-related bleeding with femoral but not radial artery access. 14 Unfortunately, the use of VCD was not examined in this prior study. Although a cost analysis is beyond the scope of this study, it was previously reported in the ACUITY trial that bivalirudin monotherapy resulted in reduced hospital costs compared with heparin plus GPI mainly because of reduced bleeding complications. 15 The potential contribution of VCD-related bleeding reduction to overall cost estimates in this patient population remains to be determined; however, it has been reported that routine use of the AngioSeal VCD was associated with a net cost savings as compared with mechanical compression. 16 Thus, several strategies may be undertaken in the future to reduce major ASB in patients with ACS managed with an invasive strategy. Several limitations of this study deserve comment. First, this was a nonrandomized, post hoc subgroup analysis that should be considered hypothesis generating for future definitive investigation. The timing of the major ASB was not recorded in ACUITY. If a major ASB developed during the angiographic or PCI procedure, it may have influenced the decision to use or not to use a VCD and may have contributed to more ASB in the non-VCD group. Second, the use of a VCD was not randomized and was left to the operator's discretion, which may have introduced a potential for selection bias and nonadjustment for unmeasured confounders, including the presence of peripheral vascular disease that was not captured in ACUITY. Several characteristics of the VCD population are associated with lower rates of bleeding. This is a limitation that should also be considered. There were 450 centers in the ACUITY trial, and the decision to use a VCD as well as the choice of which particular VCD to use was not randomized and was probably related to the preferences and experience at the individual centers. A wide range of operator experience with the various VCD also could have influenced the rates of major ASB among the various devices. The PCI subset was also underpowered to determine a significant benefit with VCD, although the risk reduction was similar to the overall population, and a trend toward lower rates of major ASB was present. Larger randomized studies are also required to definitively determine the relative rates of major ASB among the currently available VCD. Finally, this study examined only major ASB, and not other vascular complications such as pseudoaneurysm, arteriovenous fistula, and limb ischemia, the relative occurrence of which with and without VCD must be considered when determining whether to use VCD.
In summary, in the large-scale ACUITY trial, the rates of major femoral ASB were significantly lower with (1) VCD use compared with manual compression and (2) bivalirudin monotherapy compared with GPI-containing antithrombin regimens regardless of VCD usage. Major ASB rates were lowest (Ͻ1%) in patients who received both a VCD and bivalirudin monotherapy. These results suggest that the combined use of bivalirudin and a VCD may reduce major ASB in patients with ACS managed with an early invasive strategy from the femoral approach.
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